Cargando…

GM1 Gangliosidosis—A Mini-Review

GM1 gangliosidosis is a progressive, neurosomatic, lysosomal storage disorder caused by mutations in the GLB1 gene encoding the enzyme β-galactosidase. Absent or reduced β-galactosidase activity leads to the accumulation of β-linked galactose-containing glycoconjugates including the glycosphingolipi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicoli, Elena-Raluca, Annunziata, Ida, d’Azzo, Alessandra, Platt, Frances M., Tifft, Cynthia J., Stepien, Karolina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446533/ https://www.ncbi.nlm.nih.gov/pubmed/34539759 http://dx.doi.org/10.3389/fgene.2021.734878

Ejemplares similares

Myelin Abnormalities in the Optic and Sciatic Nerves in Mice With GM1-Gangliosidosis
por: Heinecke, Karie A., et al.
Publicado: (2015)

Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
por: Allende, Maria L., et al.
Publicado: (2023)

Characterization of glycan substrates accumulating in GM1 Gangliosidosis
por: Lawrence, Roger, et al.
Publicado: (2019)

A pentasaccharide for monitoring pharmacodynamic response to gene therapy in GM1 gangliosidosis
por: Kell, Pamela, et al.
Publicado: (2023)

Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis
por: Weesner, Jason Andrew, et al.
Publicado: (2022)

AAV-Mediated Gene Delivery in Adult GM1-Gangliosidosis Mice Corrects Lysosomal Storage in CNS and Improves Survival
por: Baek, Rena C., et al.
Publicado: (2010)

GM1 Gangliosidosis: Mechanisms and Management
por: Rha, Allisandra K, et al.
Publicado: (2021)

Interorganellar Membrane Microdomains: Dynamic Platforms in the Control of Calcium Signaling and Apoptosis
por: Annunziata, Ida, et al.
Publicado: (2013)

Transcription factor competition regulates lysosomal biogenesis and autophagy
por: d'Azzo, Alessandra, et al.
Publicado: (2020)

A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)
por: Davies, Elin Haf, et al.
Publicado: (2020)

Genetics and Therapies for GM2 Gangliosidosis
por: Cachón-González, María Begoña, et al.
Publicado: (2018)

Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased (1)H NMR-Linked Metabolomics Strategy
por: Percival, Benita C., et al.
Publicado: (2021)

Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice
por: Chen, Joseph C., et al.
Publicado: (2020)

Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases
por: Annunziata, Ida, et al.
Publicado: (2018)

GM1gangliosidosis: Clinical and radiological clue to diagnosis
por: Suthar, Renu, et al.
Publicado: (2012)

GM1‐Gangliosidosis Type III Associated Parkinsonism
por: Kaiyrzhanov, Rauan, et al.
Publicado: (2021)

Wishbone Sign in GM1 Type III Gangliosidosis
por: Agarwal, Ayush, et al.
Publicado: (2023)

Animal models of GM2 gangliosidosis: utility and limitations
por: Lawson, Cheryl A, et al.
Publicado: (2016)

Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis
por: Deschenes, Natalie M., et al.
Publicado: (2023)

Neuroradiological findings in GM2 gangliosidosis variant B1
por: Bano, Shahina, et al.
Publicado: (2011)

Clinical findings in Brazilian patients with adult GM1 gangliosidosis
por: Giugliani, Luciana, et al.
Publicado: (2019)

Progressive dystonia as a presenting manifestation of GM1 gangliosidosis
por: Mehta, Sahil, et al.
Publicado: (2019)

Late-infantile GM1 gangliosidosis: A case report
por: Noh, Eu Seon, et al.
Publicado: (2022)

Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis
por: Latour, Yvonne L., et al.
Publicado: (2019)

Sialylation of host proteins as targetable risk factor for COVID‐19 susceptibility and spreading: A hypothesis
por: Bongiovanni, Antonella, et al.
Publicado: (2021)

Extensive Mongolian Spots in a Hypotonic Infant with GM1 Gangliosidosis
por: Ranjan, Suprabhat, et al.
Publicado: (2018)

Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content
por: Tonin, Rodolfo, et al.
Publicado: (2019)

GM2 Gangliosidosis in Shiba Inu Dogs with an In‐Frame Deletion in HEXB
por: Kolicheski, A., et al.
Publicado: (2017)

Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis
por: Tsunogai, Toshiki, et al.
Publicado: (2022)

Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis
por: Tsunogai, Toshiki, et al.
Publicado: (2022)

GM1 GANGLIOSIDOSIS ASSOCIATED WITH NEONATAL-ONSET OF DIFFUSE ECCHYMOSES AND MONGOLIAN SPOTS
por: Dweikat, Imad, et al.
Publicado: (2011)

Genetic Analysis of Undiagnosed Juvenile GM1-Gangliosidosis by Microarray and Exome Sequencing
por: Bouhouche, Ahmed, et al.
Publicado: (2018)

Glycosphingolipids within membrane contact sites influence their function as signaling hubs in neurodegenerative diseases
por: Weesner, Jason Andrew, et al.
Publicado: (2023)

GM1‐gangliosidosis: The caregivers' assessments of symptom impact and most important symptoms to treat
por: Bingaman, Amanda, et al.
Publicado: (2022)

Cysts in White Matter: A Novel Neuroimaging Finding in Infantile GM1 Gangliosidosis
por: Kamate, Mahesh
Publicado: (2018)

Single Institutional Experience with GM1 Gangliosidosis: Clinical and Laboratory Results of 14 Patients
por: Akar, Halil Tuna, et al.
Publicado: (2022)

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis
por: Sala, Davide, et al.
Publicado: (2022)

Lysosomes and Cancer Progression: A Malignant Liaison
por: Machado, Eda R., et al.
Publicado: (2021)

Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 Gangliosidosis
por: Matsuoka, Kazuhiko, et al.
Publicado: (2011)

Cerebellar atrophy on top of motor neuron compromise as indicator of late-onset GM2 gangliosidosis
por: Hölzer, Hans Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sghurr5q08hq2eslgem1k31u8b